***Background.*** Since the advent of molecular diagnostics, there are limited epidemiologic data for respiratory viral infections (RVI) in pediatric solid organ (SOT) or hematopoietic stem cell transplant (HSCT) recipients. This study aimed to describe the epidemiology of RVI and all-cause mortality 3 months following the onset of RVI in this high-risk pediatric population.

***Methods.*** Multi-center retrospective cohort study of patients 0 to \< 18 years undergoing a SOT or HSCT between 1 January 2010 and 30 June 2013. Inpatient records were reviewed for up to 365 days post-transplant, until death or re-transplant to identify RVI. RVI was defined as a positive PCR for a viral respiratory pathogen with physician documentation of respiratory symptoms. Patients with an RVI were followed for 3-months to determine outcome.

***Results.*** A cohort of 2367 pediatric SOT and HSCT recipients (median age 6.4 yrs; range 6 days to 18 years) was identified. 382 inpatient RVI episodes were diagnosed in 341 (14.4%) patients (table) with similar RVI rates in SOT and HSCT patients (15.6% versus 17.5%, p-value = 0.2). RVI onset occurred a median of 74 days (IQR: 12 to 180) after transplant. Among the 382 RVI episodes, 425 respiratory viruses were detected by PCR. Rhinovirus/picornavirus was most commonly detected (51%), followed by RSV (17%), parainfluenza 1/2/3/4 (17%), Influenza A/B (10%), human metapneumovirus (8%), and coronavirus (2%). The all-cause mortality within 3-months of RVI onset was 7.3%.

###### 

Distribution of RVI by Type of Transplantation

  Transplant Type (N)         Patients with at least one RVI   3-Month All-cause Mortality        
  --------------------------- -------------------------------- ----------------------------- ---- --------
  All transplants             382                              (16%)                         28   (7%)
  \(2367\)                                                                                        
  SOT (1098):                                                                                     
  Lung (68)                   11                               (3%)                          0    (0%)
  Heart (249)                 46                               (12%)                         0    (0%)
  Liver (454)                 71                               (19%)                         0    (0%)
  Kidney (285)                16                               (4%)                          0    (0%)
  Intestine (20)              6                                (2%)                          3    (50%)
  Liver/intestine (5)         4                                (1%)                          1    (25%)
  Heart/lung (2)              1                                (0%)                          1    (100%)
  Other multi-visceral (15)   5                                (1%)                          1    (20%)
  HSCT (1260):                                                                                    
  Auto (351)                  49                               (13%)                         5    (10%)
  Allo (909)                  172                              (19%)                         17   (10%)

***Conclusion.*** This is the largest study of RVI in pediatric SOT and HSCT patients. Inpatient RVI is a common occurrence in the first year following HSCT or SOT, with 7% of patients dying within 3-months of RVI onset. Future investigation is warranted to define mortality attributable to RVI, to better establish the morbidity of RVI, and to identify interventions to reduce RVI.
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